When are the Patient Health Questionnaire (PHQ)-9 and Generalized Anxiety Disorder (GAD)-7 assessments performed on an inpatient unit?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Timing of PHQ-9 and GAD-7 Administration on Inpatient Units

On inpatient units, the PHQ-9 and GAD-7 should be administered at admission, daily during the hospital stay, and at discharge, with additional screening triggered by clinical changes in disease status, treatment transitions, or patient distress. 1

Initial Screening Protocol

  • Administer both PHQ-9 and GAD-7 at admission to establish baseline depression and anxiety symptom burden for all inpatients 1, 2
  • Screen using valid, reliable measures with established cutoffs (PHQ-9 cutoff ≥8 for depression; GAD-7 cutoff ≥8 for anxiety) 2, 3
  • Use a phased approach: start with the 2-item PHQ-9 screening questions (anhedonia and depressed mood), and if patients score ≥2, complete the full 9-item questionnaire 2

Ongoing Inpatient Monitoring

  • Rescreen daily for inpatients to monitor symptom trajectory and treatment response 1
  • The daily screening approach is specifically endorsed for hospitalized patients to capture rapid clinical changes 1
  • Document screening results automatically in the electronic medical record or via chart entry by clinical staff 1

Trigger-Based Screening

Beyond routine daily screening, administer PHQ-9 and GAD-7 when:

  • Changes in disease status occur (diagnosis of recurrence, progression, or new complications) 4, 2
  • Treatment transitions happen (starting new treatments, transitioning to palliative care, approaching end-of-life care) 4, 2
  • Clinical deterioration is observed (increased pain, functional decline, new symptoms) 4, 2
  • Personal crises emerge (family crisis, significant life transitions, or periods of reappraisal) 4, 2

Personnel and Administration Methods

  • Nurses, medical assistants, and social workers most commonly administer these screens on inpatient units 1
  • Administration can be via paper-and-pencil (52% of institutions), electronic tablet/computer (52%), or in-person interview (30%) 1
  • Results trigger automatic triage at some institutions (33%) or manual review and referral by clinical staff (67%) 1

Critical Safety Considerations

  • Immediately assess item 9 of the PHQ-9 (thoughts of self-harm) regardless of total score 2, 5, 6
  • If any suicidal ideation is endorsed, immediate referral for emergency psychiatric evaluation is mandatory, with one-to-one observation and interventions to ensure a safe environment 4, 2
  • Do not omit item 9 from the PHQ-9, as this artificially lowers scores and weakens predictive validity, though some institutions choose to do so 4, 2

Score Interpretation and Action Thresholds

For PHQ-9 scores:

  • 1-7 (minimal/mild): No formal treatment needed; provide patient education, verify coping skills, and plan reassessment 6
  • 8-14 (moderate): Seek consultation with psychology or psychiatry for diagnostic confirmation 4, 2
  • 15-27 (moderate-severe to severe): Immediate referral to psychology/psychiatry for diagnosis and treatment 4, 2, 5

For GAD-7 scores:

  • ≥8: Indicates clinically significant anxiety requiring further assessment 3
  • ≥10: Higher specificity for generalized anxiety disorder, though lower sensitivity 3

Common Pitfalls to Avoid

  • Do not fail to rescreen inpatients daily, as symptom burden can change rapidly during hospitalization 1
  • Never skip assessment of suicidal ideation (PHQ-9 item 9), even when total scores are low, as patients can have low overall scores but still endorse self-harm thoughts 2, 6
  • Avoid using only the total score without reviewing individual item endorsements, particularly the self-harm item 2
  • Do not initiate treatment based solely on screening scores without comprehensive clinical assessment, as these are screening tools, not diagnostic instruments 7, 8

Practical Implementation Notes

  • The PHQ-9 and GAD-7 show strong correlation (Spearman's rho = 0.74), with 78.4% of concurrent scores within 4 points of each other 9
  • Both measures demonstrate excellent internal consistency and reliability in various populations 10, 7, 8
  • Follow-up screening should continue at discharge and at subsequent outpatient visits (every 30-90 days or at clinical triggers) 1

References

Guideline

update on the implementation of nccn guidelines for distress management by nccn member institutions.

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

Guideline

Treatment for Moderate to Severe Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Mild Depressive Symptoms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

How should I score the Patient Health Questionnaire‑9 (PHQ‑9) and the Generalized Anxiety Disorder‑7 (GAD‑7)?
How do I interpret and manage Patient Health Questionnaire‑9 (PHQ‑9) and Generalized Anxiety Disorder‑7 (GAD‑7) scores?
How often should a patient complete the GAD‑7 (Generalized Anxiety Disorder‑7), PHQ‑9 (Patient Health Questionnaire‑9), MDQ (Mood Disorder Questionnaire), and CASE‑I (Clinical Assessment of Severity of Episodes) scales, and when should laboratory monitoring be performed?
What should be added to a patient's sertraline (Zoloft) regimen for persistent anxiety and depression, with a GAD-7 (Generalized Anxiety Disorder 7) score of 20 and PHQ-9 (Patient Health Questionnaire-9) score of 15?
What medication adjustments are recommended for a patient with GAD, MDD, PTSD, and ADHD, with high PHQ-9 and GAD-7 scores, and currently taking duloxetine (Cymbalta), buspirone (Buspar), bupropion (Wellbutrin), and hydroxyzine (Vistaril), who reports inadequate symptom relief?
What are the treatment options for heavy bleeding in patients with End-Stage Renal Disease (ESRD) on dialysis who are unresponsive to progesterone-only therapy?
What are the guidelines for postoperative care to improve flap survival after free flap surgery?
What is the recommended meal plan for a patient 2 weeks post-operative from a small bowel resection?
Why does Mounjaro (tirzepatide) cause headaches and migraines?
What are the implications and recommended next steps for abnormal nerve conduction velocity test results indicating potential nerve dysfunction?
What are the next steps for a patient on a maintenance inhaler who is using their rescue inhaler (inhaler containing a short-acting beta-agonist (SABA)) two times a day?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.